Ecomax EMAX · USD

Its shares trade under the ticker EMAX. It has been listed since 12 July 2001. In the fiscal year to 30 June 2023, it reported revenue of $424,391 and a net loss of $89,920. At that date it held total assets of $168,506 and shareholders' equity of −$297,610.

Ecomax, Inc. engages in the search for new business opportunities. The company is headquartered in New York City, New York. The company went IPO on 2001-07-12. Rocitin NMN is a nutritional supplement manufactured by Pharmazeutische Fabrik Evers GmbH & Co. KG, a German company. Each bottle contains 60 capsules, 10080 mg of NMN. NMN, as β-Nicotinamide Mononucleotide exists in some fruits, vegetables, and poultry. The company is a molecule naturally occurring in all life forms and can be transformed into a significant coenzyme NAD+ within cells, which is important to human metabolism. Its research, including Nicotinamide mononucleotide (NMN) as an anti-aging health product has shown that NAD+ levels in the body will decrease with age, and that exogenous supplementation of NMN enhances NAD+ levels and thus the function of human cells. In addition, NMN also helps to repair broken DNA, regulate the stability of DNA and cell death, and improve neurodegenerative and metabolic conditions.

Figures and description from our data supplier, not checked against the company's own report.

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.